Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV metoprolol for ARDS in ICU (randomized, double-blind, placebo-controlled)
2022-002494-28Phase 3Active
- Sponsor
- Centro de Investigación Biomédica en Red
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing IV metoprolol tartrate with Placebo IV (2 arms). Primary endpoints: 28-day survival and Ventilator-free days within 28 days. Started Mar 2023; status: active.
02
Drugs
metoprolol
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2022-002494-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002494-28.